These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27133877)

  • 1. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults.
    Leroux-Roels G; Van Damme P; Haazen W; Shakib S; Caubet M; Aris E; Devaster JM; Peeters M
    Vaccine; 2016 Jun; 34(27):3156-3163. PubMed ID: 27133877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
    Wilkinson TMA; Schembri S; Brightling C; Bakerly ND; Lewis K; MacNee W; Rombo L; Hedner J; Allen M; Walker PP; De Ryck I; Tasciotti A; Casula D; Moris P; Testa M; Arora AK
    Vaccine; 2019 Sep; 37(41):6102-6111. PubMed ID: 31447126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity and safety of a non-typeable
    De Smedt P; Leroux-Roels G; Vandermeulen C; Tasciotti A; Di Maro G; Dozot M; Casula D; Annaratone M; Riccucci D; Arora AK
    Vaccine X; 2021 Dec; 9():100124. PubMed ID: 34820619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine.
    Van Damme P; Leroux-Roels G; Vandermeulen C; De Ryck I; Tasciotti A; Dozot M; Moraschini L; Testa M; Arora AK
    Vaccine; 2019 May; 37(23):3113-3122. PubMed ID: 31029515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.
    Galgani I; Annaratone M; Casula D; Di Maro G; Janssens M; Tasciotti A; Schwarz T; Ferguson M; Arora AK
    Respir Res; 2022 May; 23(1):114. PubMed ID: 35509077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
    Levy J; Licini L; Haelterman E; Moris P; Lestrate P; Damaso S; Van Belle P; Boutriau D
    Hum Vaccin Immunother; 2015; 11(3):620-31. PubMed ID: 25715157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
    Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study.
    Togashi T; Mitsuya N; Kogawara O; Sumino S; Takanami Y; Sugizaki K
    Vaccine; 2016 Aug; 34(38):4635-4641. PubMed ID: 27265451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.
    Szenborn L; Osipova IV; Czajka H; Kharit SM; Jackowska T; François N; Habib MA; Borys D
    Vaccine; 2017 Sep; 35(40):5331-5338. PubMed ID: 28866290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan.
    Lin TY; Lu CY; Chang LY; Chiu CH; Huang YC; Bock HL; Tang H; François N; Moreira M; Schuerman L; Huang LM
    J Formos Med Assoc; 2012 Sep; 111(9):495-503. PubMed ID: 23021506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the non-typable
    Galgani I; Põder A; Jõgi R; Anttila VJ; Milleri S; Borobia AM; Launay O; Testa M; Casula D; Grassano L; Tasciotti A; Dozot M; Arora AK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2187194. PubMed ID: 36974988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
    Andreas S; Testa M; Boyer L; Brusselle G; Janssens W; Kerwin E; Papi A; Pek B; Puente-Maestu L; Saralaya D; Watz H; Wilkinson TMA; Casula D; Di Maro G; Lattanzi M; Moraschini L; Schoonbroodt S; Tasciotti A; Arora AK; Maltais F;
    Lancet Respir Med; 2022 May; 10(5):435-446. PubMed ID: 35026180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
    Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
    Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.